The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Clinical trial NCT07203729 · RECRUITING
Trial details
- NCT number
- NCT07203729
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2030-06-15
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.